Netherlands-based diagnostics firm Qiagen is to work with the Chittaranjan National Cancer Institute to establish the first large-scale cervical cancer screening program for women in Kolkata, India.
The Qiagencares Kolkata Project will use Qiagen's hybrid capture human papillomavirus DNA testing technology to screen women for cancer-causing types of HPV to identify those with, or at risk of, developing cervical cancer. The project also includes educational campaigns to raise awareness about HPV, cervical cancer, and other women's health issues. The initiative will be conducted over five years and is expected to reach 50,000 women.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze